Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generic Imiquimod vs Zyclara in Actinic Keratosis
NCT02120898Phase 3Completed
- Sponsor
- Allergan
- Start
- Oct 2013
- Primary completion
- Apr 2014
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of imiquimod in actinic keratosis (AK) (3 arms), sponsored by Allergan. Primary endpoint: Complete Clearance Rate - Percentage of Participants With Treatment Success at Week 14. Started Oct 2013; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02120898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120898.